Streetbeat News

Products Services

DFLI

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) reported its financial and operational results for Q3 2024, highlighting its position as a leader in energy storage with its Battle Born Batteries®.

Portfolio Pulse from

November 14, 2024 | 9:30 pm

CELC

Celcuity Inc. (Nasdaq: CELC) reported its third quarter financial results and provided a corporate update. The company is focused on developing targeted therapies for oncology.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

AQMS

Aqua Metals has reported its third quarter 2024 results, highlighting progress in operational achievements and commercial development. The company has successfully produced high-purity, battery-grade lithium carbonate from its pilot operations and is working on advancing financing and commercial agreements.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

MOVE

Movano Health reported its Q3 2024 financial results, highlighting the successful restocking of the Evie Ring and updates on the EvieMED 510(k) application. The company is focusing on launching EvieMED and securing B2B opportunities.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

SMCI

Super Micro Computer's stock is declining due to increased competition in the AI server market, adding to its existing struggles with investors.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

SNTI

Senti Bio has announced its third quarter 2024 results, highlighting ongoing enrollment in the Phase 1 clinical trial of SENTI-202 for treating relapsed/refractory hematologic malignancies, including AML. Initial clinical data is expected in Q4 2024.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

VUZI

Vuzix Corporation reported its financial results for the third quarter of 2024, highlighting its strategic progress in the Smart Glasses and Augmented Reality sectors.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

SPRO

Spero Therapeutics reported its Q3 2024 financial results, highlighting a cash balance of $76.3M and a cash runway into mid-2026. The Phase 3 PIVOT-PO trial for tebipenem HBr is on track for completion in the second half of 2025.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

GTBP

GT Biopharma, Inc. (NASDAQ: GTBP) announced its third quarter 2024 financial results. The company is a clinical stage immuno-oncology firm focused on developing therapeutics using its NK cell engager TriKE® platform.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

ATXI

Avenue Therapeutics has released its Q3 2024 financial results and highlighted recent corporate developments. The company anticipates topline data from its Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy by the end of 2024.

Portfolio Pulse from

November 14, 2024 | 9:15 pm